Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Hoffmann-La Roche481 enrolled

Overview

This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

481

Conditions

Metastatic Breast Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. * ECOG performance status of 0 or 1 * For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception * For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: * HER2-positive status * Prior chemotherapy for locally recurrent or metastatic disease * Prior hormonal therapy \< 2 weeks prior to randomization * Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization * Investigational therapy within 28 days of randomization General Medical Exclusions: * Life expectancy of \< 12 weeks * Inadequate organ function * Uncontrolled serious medical or psychiatric illness * Active infection requiring intravenous (IV) antibiotics at screening * Pregnancy or lactation * History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death

Locations (178)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Arizona Cancer Center

Tucson, Arizona, United States

Wilshire Oncology Medical Group

Corona, California, United States

Wilshire Oncology Medical Group

Glendora, California, United States

Wilshire Oncology Medical Group

La Verne, California, United States

Outcomes

Primary Outcomes

Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population

Tumor assessment was performed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator. Disease progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), unequivocal progression of existing non-target lesions, or presence of new lesions.

Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Progression Free Survival (PFS) in ITT Population

PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Tumor assessment was performed as per RECIST v1.1 by investigator. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.

Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Percentage of Participants With Progression or Death in High Baseline Plasma Vascular Endothelial Growth Factor-A (VEGF-A) ITT Population

Tumor assessment was performed as per RECIST v1.1 by investigator. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions.

Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks)

PFS in High Baseline Plasma VEGF-A ITT Population

Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks)

Secondary Outcomes

Percentage of Participants Who Died - ITT Population

Time frame: From randomization till death or clinical cut-off (up to 244 weeks)

Overall Survival (OS) - ITT Population

OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

Time frame: From randomization till death or clinical cut-off (up to 244 weeks)

Percentage of Participants Who Died - High Baseline Plasma VEGF-A ITT Population

Time frame: From randomization till death or clinical cut-off (up to 244 weeks)

OS - High Baseline Plasma VEGF-A ITT Population

OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

Time frame: From randomization till death or clinical cut-off (up to 244 weeks)

Percentage of Participants With an Objective Response - ITT Population

Objective response was defined as having a Complete Response (CR) or Partial Response (PR) according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Measurable disease was defined by the presence of at least one measurable lesion by clinical measurement, chest x-ray, computed tomography (CT), or magnetic resonance imaging (MRI).

Time frame: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Percentage of Participants With an Objective Response - High Baseline Plasma VEGF-A ITT Population

Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Measurable disease was defined by the presence of at least one measurable lesion by clinical measurement, chest x-ray, CT, or MRI.

Duration of Response - ITT Population

Duration of response was defined as the time from the initial date of the objective response to documented disease progression or death (whichever occurred first). Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. Analysis was performed using Kaplan Meier method.

Time frame: Baseline, every 8 weeks until documented disease progression or clinical cut-off (up to 117.7 weeks)

Duration of Response - High Baseline Plasma VEGF-A ITT Population

Duration of response was defined as the time from the initial date of the objective response to documented disease progression or death (whichever occurred first). Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. Analysis was performed using Kaplan Meier method.

Time frame: Baseline, every 8 weeks until documented disease progression or clinical cut-off (up to 111.3 weeks)